EURAP is a prospective observational study
of pregnancies with antiepileptic drugs (AEDs)

The well-being of women with epilepsy and their offspring is of great concern. Our aim is to contribute to a better understanding of the risks associated with antiepileptic drugs during pregnancy.

What we need is the collaboration of physicians from all corners of the world to join forces.

Objectives

The primary goal is to compare the risk of major congenital malformations following maternal intake of Antiepileptic drugs.

Why a pregnancy registry?

The use of AEDs during pregnancy is associated with an increased risk of birth defects.

Funding and support

EURAP is an independent research initiative promoted and implemented by physicians working on a non-profit basis.

It was launched in Europe in 1999 by a consortium of independent research groups and later extended to several other nations worldwide. The aim was to collect data on the risk of antiepileptic drugs during pregnancy and share it in an international registry.

At present, physicians from 44 countries in Europe, Oceania, Asia and Latin America are actively collaborating, and more than 24,600 pregnancies have been registered.

18421 enrolled pregnancies
44 countries from Europe, Australia, Asia and latin America

Stay tuned and do not miss the chance to collaborate.